Narrative review· 2020

From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase

Hallberg M|Nyberg F

Frontiers in Pharmacology

DOI: 10.3389/fphar.2020.590581
PubMed: 33178027
Evidence level: moderate
Verification: verified

Summary

Review of angiotensin IV, the AT4 binding site and insulin-regulated aminopeptidase inhibitor development.

Limitations

Narrative review|Evidence is mainly preclinical|Native peptide has poor drug-like properties|No established human treatment

Linked peptides

Angiotensin IV

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.